PPTA Twitter

PlasmaProteins
PlasmaProteins Amy Efantis, President & CEO of @PlasmaProteins is grateful for all plasma donors and plasma collectors. Read more here: bit.ly/2N4ExoU pic.twitter.com/rWLUcZ9COe
6 days ago.
PlasmaProteins
PlasmaProteins “Ultimately, what drives my colleagues on the Board, my company, and the staff at PPTA is a focus on patients...” Karen Etchberger, of @CSLBehring , reflects on her election as Chair of @plasmaproteins Global Board of Directors. bit.ly/2u61VeZ pic.twitter.com/QKhDPwL1e0
7 days ago.

PPTA Attends the 114th Meeting of the FDA Blood Products Advisory Committee (BPAC)

On Nov. 17-18, the 114th meeting of the FDA Blood Products Advisory Committee (BPAC) was held. During BPAC's discussion of strategies to manage iron deficiency associated with blood donation in the morning of Nov. 17, PPTA presented results of the Association's study of ferritin levels in Source Plasma donors.

PPTA concluded that our data confirm that iron depletion and deficiency are not outcomes of frequent Source Plasma donation; thus, measures needed to protect whole blood and platelet donors are not needed for Source Plasma donors. BPAC agreed that the available scientific evidence confirm that iron supplementation in blood donors mitigates iron deficiency and improves hemoglobin recovery. BPAC also agreed that the available scientific evidence supports the need for routine monitoring of iron stores:

  • Without effective iron supplementation: for all blood donors, frequent donors (male and female), and premenopausal female donors.
  • With effective iron supplementation: for frequent donors (male and female) and premenopausal female donors, but not for all blood donors.

In the afternoon of Nov. 17, BPAC discussed proposed procedures for assuring donor safety for collections of blood from female donors with hemoglobin values of 12.0–12.4 g/dL. BPAC then discussed adverse reactions related to blood donation in teenage (16- to 18-year-olds) donors and the effectiveness of several mitigation measures. BPAC agreed unanimously that the available evidence: indicates that adverse reactions and injuries after blood donation in teenage donors are notable enough concern to require intervention; support applying the donor-specific criterion of estimated blood volume >3500 mL as a means to reduce donor reactions; and suggest that teenage blood donors are susceptible to developing iron deficiency. BPAC also agreed that the available data indicate that the specific measure of applied muscle tension is effective to minimize reactions.

 

In the morning of Nov. 18, BPAC heard an informational session on the Zika virus and blood safety in the U.S. BPAC then heard presentations on the Transfusion Transmissible Infections Monitoring System and the FDA workshop on preclinical evaluation of red blood cells for transfusion. PPTA thanks BPAC Industry Representative Toby Simon, M.D. (CSL Behring), whose term ended on November 18, for his service since 2012.

bpac, FDA, Plasma donors, Zika

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100